Urinary Leukotriene E4 and Prostaglandin D2 Metabolites Increase in Adult and Childhood Severe Asthma Characterized by Type-2 Inflammation by Kolmert, Johan et al.
 
 
Urinary leukotriene E4 and prostaglandin D2 metabolites increase in adult and 1 
childhood severe asthma characterized by type-2 inflammation 2 
 3 
Johan Kolmert 1,2,3, Cristina Gómez 1,2,3, David Balgoma 1,2,3, Marcus Sjödin 1,2,3, Johan Bood 4 
1,3,4, Jon R Konradsen 3,5,6 , Magnus Ericsson 7, John-Olof Thörngren 7, Anna James 1,3, Maria 5 
Mikus 1,3, Ana R. Sousa 8, John H. Riley 8, Stewart Bates 8, Per S. Bakke 9, Ioannis Pandis 10, 6 
Massimo Caruso 11, Pascal Chanez 12, Stephen J. Fowler 13, Thomas Geiser 14, Peter Howarth 7 
15, Ildikó Horváth 16, Norbert Krug 17, Paolo Montuschi 18, Marek Sanak 19, Annelie Behndig 20, 8 
Dominick E. Shaw 21, Richard G. Knowles 22, Cécile TJ. Holweg 23, Åsa M. Wheelock 24, 9 
Barbro Dahlén 3,4, Björn Nordlund 1,5,6, Kjell Alving 25, Gunilla Hedlin 3,5, Kian Fan Chung 10, 10 
Ian M. Adcock 10, Peter J. Sterk 26, Ratko Djukanovic 15, *Sven-Erik Dahlén 1,3, *Craig E. 11 
Wheelock 2,3, on behalf of the U-BIOPRED Study Group# 12 
 13 
 14 
Affiliations:  15 
1) The Institute of Environmental Medicine, Karolinska Institutet (KI), Stockholm, Sweden 16 
2) Division of Physiological Chemistry 2, Department of Medical Biochemistry and 17 
Biophysics, KI. 18 
3) The Centre for Allergy Research, KI. 19 
4) Department of Medicine Huddinge, KI and Karolinska University Hospital (KUH), 20 
Stockholm, Sweden. 21 
5) Department of Women’s and Children’s Health, KI. 22 
6) Astrid Lindgren Children's Hospital, KUH. 23 
7) Department of Clinical Pharmacology Huddinge, KI and KUH. 24 
 
 
8) Glaxo Smith Kline, U.K. Respiratory Therapeutic Unit, Stockley Park, United Kingdom 25 
(U.K). 26 
9) Institute of Medicine, University of Bergen, Bergen, Norway. 27 
10) National Heart and Lung Institute and Department of Computing & Data Science 28 
Institute, Imperial College London, U.K. 29 
11) Department of Clinical and Experimental Medicine and Department of Biomedical and 30 
Biotechnological Sciences, University of Catania, Catania, Italy. 31 
12) Assistance Publique des Hôpitaux de Marseille, Clinique des Bronches, Allergies et 32 
Sommeil, Aix Marseille Université, Marseille, France. 33 
13) Division of Infection, Immunity and Respiratory Medicine, School of Biological 34 
Sciences, Faculty of Biology, Medicine and Health, University of Manchester, and 35 
Manchester Academic Health Science Centre and NIHR Biomedical Research Centre, 36 
Manchester University Hospitals NHS Foundation Trust, Manchester, U.K. 37 
14) Department of Pulmonary Medicine, University Hospital Bern, Bern, Switzerland. 38 
15) Faculty of Medicine, Southampton University and NIHR Southampton Respiratory 39 
Biomedical Research Center, University Hospital Southampton, Southampton, U.K. 40 
16) Department of Pulmonology, Semmelweis University, Budapest, Hungary. 41 
17) Fraunhofer Institute for Toxicology and Experimental Medicine, Hannover, Germany. 42 
18) Department of Pharmacology, Catholic University of the Sacred Heart, and Fondazione 43 
Policlinico Universitario Agostino Gemelli IRCCS, Rome, Italy. 44 
19) Department of Internal Medicine, Jagiellonian University Medical College, Cracow, 45 
Poland. 46 
20) Department of Public Health and Clinical Medicine, Section of Medicine, Umeå 47 
University, Umeå, Sweden. 48 
21) Nottingham NIHR Biomedical Research Centre, University of Nottingham, U.K. 49 
 
 
22) Knowles Consulting, Stevenage Bioscience Catalyst, Stevenage, U.K. 50 
23) Genentech Inc. South San Fransisco, CA, USA. 51 
24) Respiratory Medicine Unit, Department of Medicine Solna and Center for Molecular 52 
Medicine (KI). 53 
25) Department of Women's and Children's Health, Uppsala University, Uppsala, Sweden. 54 
26) Department of Respiratory Medicine, Amsterdam UMC, University of Amsterdam, 55 
Amsterdam, The Netherlands. 56 
 57 
 58 
#Ahmed H, Auffray C, Bansal AT, Bel E H, Bigler J, Billing B, Baribaud F, Bisgaard H, 59 
Boedigheimer M J, Bønnelykke K, Brandsma J, Brinkman P, Bucchioni E, Burg D, Bush A, 60 
Chaiboonchoe A, Compton CH, Corfield J, Cunoosamy D, D’Amico A, De Meulder B, 61 
Erpenbeck V J, Erzen D, Fichtner K, Fitch N, Fleming L J, Formaggio E, Frey U, Gahlemann 62 
M, Goss V, Guo Y, Hashimoto S, Haughney J, Hekking P W, Higenbottam T, Hohlfeld J M, 63 
Knox A J, Lazarinis N, Lefaudeux D, Loza M J, Lutter R, Manta A, Masefield S, Matthews J 64 
G, Mazein A, Meiser A, Middelveld R J M, Miralpeix M, Mores N, Murray C S, Musial J, 65 
Myles D, Pahus L, Pavlidis S, Postle A, Powel P, Praticò G, PuigValls M, Rao N, Roberts A, 66 
Roberts G, Rowe A, Sandström T, Schofield JPR, Seibold W, Selby A, Sigmund R, Singer F, 67 
Skipp P J, Smicker M, Sun K, Thornton B, Uddin M, van Aalderen W M, van Geest M, 68 
Vestbo J, Vissing N H, Wagener A H, Wagers S S, Weiszhart Z, Wilson S J, Östling J.  69 
 70 
 71 
This article has an online data supplement, which is accessible from this issue's table of 72 





*To whom contact should be addressed: 76 
 77 
 78 
*Craig E Wheelock, Assoc. Prof.  79 
Division of Physiological Chemistry II 80 
Department of Medical Biochemistry and Biophysics  81 
Karolinska Institutet 82 
Solnavägen 9, Biomedicum Quartier 9A 83 
171 77 Stockholm, Sweden 84 
Telephone: +46-733-66 85 88 85 
Email: craig.wheelock@ki.se 86 
 87 
 88 
*Sven-Erik Dahlén, Prof. 89 
Experimental Asthma and Allergy Research Group 90 
The Institute of Environmental Medicine 91 
Karolinska Institutet 92 
Solnavägen 9, Biomedicum Quartier 5B 93 
171 77 Solna, Stockholm, Sweden 94 
Telephone: +46-8-5248 7203 95 






Author Contributions: ARS, JHR, SB, PSB, KFC, MC, PC, AD, SJF, TG, PH, IH, NK, PM, 100 
MS, AB, DES, IP, RGK, BD, IMA, JRK, BN, KA, GH, PJS,RD, SED and CEW designed the 101 
studies. DB, JO, ARS, JHR, SB, PSB, KFC, MC, PC, AD, SJF, TG, PH, IH, NK, PM, MS, 102 
AB, DES, IP, RGK, BD, IMA, JRK, BN, KA, GH, PJS, RD and SED executed the clinical 103 
studies. JK, CG, DB, MS, ME, JB, JRK, BN, CTJH, KA, GH, MM and AJ acquired and 104 
analyzed the data. JK, CG, MS, JRK, AMW, SED and CEW interpreted the data. JK, CG, 105 
JRK, MM, SJF, AB, DES, RGK, PJS, RD, SED and CEW wrote the manuscript draft, which 106 




This project has received funding from the Innovative Medicines Initiative 2 Joint 111 
Undertaking (JU) under grant agreement No 115010 (U-BIOPRED) and 831434 for 3TR 112 
(Taxonomy, Targets, Treatment, and Remission). The JU receives support from the European 113 
Union’s Horizon 2020 research and innovation programme and EFPIA (European Federation 114 
of Pharmaceutical Industries and Associates). Grants were also received from the Swedish 115 
Heart-Lung Foundation, Swedish Research Council (2014-26826, 2014-3281, 2016-02798, 116 
2016-0338, 2018-02851), the Konsul Th C Berghs research foundation, the ChAMP (Centre 117 
for Allergy Research Highlights Asthma Markers of Phenotype) consortium, which is funded 118 
by the Swedish Foundation for Strategic Research, the Karolinska Institutet, AstraZeneca & 119 
Science for Life Laboratory Joint Research Collaboration, and the Vårdal Foundation. A 120 
James was supported by the Osher Initiative for Severe Asthma Research. CE Wheelock was 121 
supported by the Swedish Heart Lung Foundation (HLF 20180290). K Alving was supported 122 
by the Swedish Government Agency for Innovation Systems (SAMBIO program). The 123 
Swedish Search study was funded by the Freemason Child House Foundation in Stockholm, 124 
 
 
the Konsul Th. C. Bergh's Foundation, the Swedish Asthma and Allergy Association's 125 
Research Foundation, the Centre for Allergy Research at Karolinska Institutet and the 126 
Swedish Heart-Lung Foundation. B Nordlund was supported by Swedish Heart-Lung 127 
Foundation (20160338), Swedish Asthma and Allergy Research Foundation (F2018-0016) 128 
and Stockholm County Council (LS 2018-0792). J.R. Konradsen was supported by 129 
Stockholm County Council (K0138-2015 no 5). 130 
 131 
Running Title: Urinary eicosanoids in the U-BIOPRED study 132 
 133 
Descriptor #: 5.2 Eicosanoids, Immune Effects 134 
  135 
 
 
At a Glance Commentary  136 
Scientific Knowledge on the Subject 137 
Eicosanoids may exert pro- and anti-inflammatory actions contributing to the pathobiology of 138 
asthma.  However, their relative abundance in asthmatics and association with type 2 (T2) 139 
asthma are unclear.  In addition, the influence of oral corticosteroid treatment upon 140 
eicosanoid levels is debated.  141 
 142 
What This Study Adds to the Field 143 
Urinary levels of 11 eicosanoid metabolites were quantified in 597 subjects participating in 144 
the U-BIOPRED study.  From normal values established in 100 healthy subjects, we 145 
observed a progressive increase in most metabolites in relation to asthma severity.  We 146 
demonstrate that eicosanoid levels were independent of oral corticosteroid treatment, whereas 147 
subjects on anti-IgE therapy had lower levels of LTE4 and PGD2-metabolites.  Moreover, a 148 
strong relationship between LTE4 and PGD2-metabolites and markers of T2 inflammation 149 
was validated internally, and externally using adolescents with severe or controlled persistent 150 
asthma.  An exploratory benchmarking analysis suggested that the strength of the association 151 
of urinary LTE4 and T2 asthma was in the same range as for blood eosinophils and exhaled 152 
nitric oxide (FENO).  We propose that urinary LTE4 and PGD2-metabolites should be 153 
explored as new non-invasive biomarkers to guide molecular phenotyping of asthma and the 154 





Abstract  158 
Rationale: New approaches are needed to guide personalized treatment of asthma. 159 
Objective: To test if urinary eicosanoid metabolites can direct asthma phenotyping. 160 
Methods: Urinary metabolites of prostaglandins (PG), cysteinyl-leukotrienes (LT) and 161 
isoprostanes were quantified in the Unbiased Biomarkers for the Prediction of Respiratory 162 
Diseases Outcomes (U-BIOPRED) study including 86 adults with mild-to-moderate asthma 163 
(MMA), 411 with severe asthma (SA), and 100 healthy controls (HC).  Validation was 164 
performed in 302 SA subjects followed-up after 12-18 months, and externally in 95 165 
adolescents with asthma. 166 
Measurement and Main Results: Metabolite levels in HC were unrelated to age, BMI and 167 
sex, except for the PGE2-pathway.  Eicosanoid levels were generally greater in MMA relative 168 
to HC, with further elevations in SA, except for PGE2-metabolites in males, which were the 169 
same or lower in non-smoking asthmatics as in HC.  Metabolite levels were unchanged in 170 
asthmatics adherent to oral corticosteroid treatment as documented by urinary prednisolone 171 
detection, whereas SA treated with omalizumab had lower levels of LTE4 and the PGD2 172 
metabolite 2,3-dinor-11β-PGF2α.  High levels of LTE4 and PGD2-metabolites were associated 173 
with lower lung-function, and increased levels of exhaled nitric oxide and eosinophil markers 174 
in blood, sputum and urine in U-BIOPRED and in adolescents with asthma.  These type-2 175 
(T2) asthma associations were reproduced in the follow-up visit of the U-BIOPRED study, 176 
and found to be as sensitive to detect T2 inflammation as the established biomarkers.   177 
Conclusions: Monitoring of urinary eicosanoids can identify T2 asthma and introduces a new 178 
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Introduction  187 
Many of the new biological treatments of asthma target type 2 (T2) asthma where mast cells, 188 
eosinophils, and the cytokines IL-4, IL-5 and IL-13 mediate central components of the 189 
inflammatory reactions (1).  However, stratification of patients for treatment is at present 190 
limited to measures of blood or sputum eosinophils, exhaled nitric oxide (FENO), or protein 191 
markers in blood such as total IgE or periostin that do not provide consistent information (2).  192 
There is accordingly an unmet need to identify new predictive biomarkers to improve 193 
stratification of patients by pathobiological mechanisms and to aid selection of treatments.   194 
Herein we report data from the pan-European U-BIOPRED study (Unbiased 195 
Biomarkers for the Prediction of Respiratory Disease outcomes) on potential urinary lipid 196 
biomarkers of asthma (3).  Leukotrienes (LTs), prostaglandins (PGs) and related arachidonic 197 
acid derivatives, collectively termed eicosanoids, are fundamental signaling molecules in 198 
human biology (4), implicated in the pathophysiology of asthma.  Specifically, the 199 
biologically active eicosanoids may exert anti- and pro-inflammatory actions, and many cause 200 
bronchoconstriction (Figure 1).  Whereas prostaglandins and thromboxane (TX) A2 are 201 
biosynthesized in enzymatic reactions initially catalyzed by either of two cyclooxygenases 202 
(COX-1 or COX-2), the LTs are generated via a pathway initiated by the 5-lipoxygenase (5-203 
LOX) enzyme.  Cysteinyl-leukotrienes (CysLT: LTC4, LTD4 and LTE4) are potent 204 
bronchoconstrictive (5) and pro-inflammatory mediators (6); CysLT1 receptor antagonists 205 
and the 5-LOX inhibitor zileuton are used for the treatment of asthma (7, 8).  Prostaglandin 206 
D2 is the major COX-product in mast cells with bronchoconstrictive and pro-inflammatory 207 
actions (9, 10), and is currently investigated as a potential new target for asthma therapy.  The 208 
isoprostanes are primarily generated non-enzymatically under conditions of oxidative stress 209 
(11), and reported biological effects in the airways suggest they may contribute to the 210 
pathophysiology of asthma (12). 211 
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The eicosanoids are short-lived in the tissues in which they are biosynthesized, and 212 
rapidly removed from circulation for excretion by the kidney.  The amounts excreted into the 213 
voided urine therefore represent an integration of the systemic load since the previous 214 
emptying of the urinary bladder.  The measurement of metabolites in the urine that reflect 215 
activation of the different biosynthetic pathways is a reliable method to assess in vivo 216 
production of primary eicosanoids (13–15).  In contrast, their levels in blood are low, 217 
fluctuating, and interpretations can be complicated by artefactual formation during sampling.  218 
In the current study, we present the largest evaluation to date of multiple urinary 219 
eicosanoid metabolites present in healthy and asthmatic adults.  We show that profiling of 220 
lipid mediators in the urine provides a valuable non-invasive approach for molecular 221 
phenotyping of asthma, and in particular provide data from two patient cohorts demonstrating 222 
that urinary LTE4 and metabolites of PGD2 correlate with eosinophilic T2 inflammation.  223 
Some of the results of these studies have been previously reported in the form of abstracts 224 
(16, 17). 225 
  226 
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Methods  227 
Cohort descriptions  228 
The U-BIOPRED study (ClinicalTrials.Gov: NCT01976767) was approved by the ethics 229 
committees at each of the 16 clinical sites and included adult subjects aged 18-79 years with 230 
either controlled mild-to-moderate asthma (MMA, n=86), or severe asthma (SA, n=411), 231 
classified according to the international guidelines for severe asthma (18).  The subjects with 232 
severe asthma were stratified by smoking status into smokers (SAs/ex, n=109), including 233 
current or past smokers (>5 pack years), and nonsmokers (SAn).  Clinical study data for the 234 
baseline cross-sectional examination have been published previously (3), but essential 235 
outcomes including medication use are described in Table 1.  Level of treatment with inhaled 236 
corticosteroids (ICS) was one inclusion criterium (≤500 µg fluticasone equivalents/day in 237 
MMA, and ≥1000 µg fluticasone equivalents/day in SA).  A total of 41% of the severe 238 
asthmatics were prescribed oral corticosteroids (OCS) and 13% were treated with 239 
omalizumab.  No subjects were treated with 5-LOX inhibitors or prescribed non-steroidal 240 
anti-inflammatory drugs (NSAIDs) for regular use.  A control group of healthy participants 241 
(HC, n=100) was included.  The findings in the baseline study were internally validated in 242 
302 subjects with severe asthma followed-up in a longitudinal visit after 12-18 months.  243 
External validation was conducted in 95 adolescent subjects aged 10-16 years with severe or 244 
controlled persistent asthma from the Swedish Search cohort.  Subject characteristics 245 
including use of ICS as budesonide equivalents are summarized in Table 2. (19).  The 246 
Swedish Search study was approved by the regional board of ethics at Karolinska Institutet 247 
(Dnr 2006/1324-31/1).  Written informed consent was obtained from all participants or their 248 
guardians.  In all studies, spot samples of urine were collected and stored at -80°C without 249 




Quantification of eicosanoid metabolites 252 
For the mass spectrometry analysis, urine samples were randomly distributed into batches of 253 
24 samples, each of which included one quality control (QC) reference sample.  Eicosanoid 254 
metabolites (Figure 1) and creatinine were quantified as previously published (20).  Among 255 
the 13 metabolites representing key pathways (Figure 1), 2,3-dinor-6-keto-PGF1α and TXB2 256 
displayed unacceptable technical variability (>40% coefficient of variation across batches) 257 
and were excluded from the final analysis.  Missing values (i.e., lower than the limit of 258 
quantification) occurred in <0.6% and 3.2% of the baseline and longitudinal samples 259 
respectively.  In adolescent urine samples, the PGD2- and CysLT-metabolites were quantified 260 
using enzyme immunoassays (EIA) from Cayman Chemical (Ann Arbor, US) as previously 261 
described (9).  Eosinophil-derived neurotoxin (EDN) was measured according to the 262 
manufacturer’s instruction using a kit from Medical & Biological Laboratories Co. (Naka-Ku 263 
Nagoya, Japan).   264 
 265 
Data analysis 266 
Associations between U-BIOPRED baseline or longitudinal eicosanoid concentrations and 267 
clinical or hematological markers of asthma were evaluated using an extreme value approach, 268 
where asthmatic subjects were stratified by high (75th percentile) or low (25th percentile) 269 
urinary concentrations of LTE4, combined PGD2-metabolites (c-PGD2), and a combined 270 
isoprostane variable (c-isoprostanes).  The composite variables were created by log2-271 
transformation followed by scaling each analyte to unit variance (i.e., z-score) before 272 
summation at the subject level.  The same associations were evaluated for CysLTs and PGD2-273 
metabolites in the Swedish Search study. Eicosanoid variables followed a non-normal 274 
distribution.  Outcome variables were collected from the U-BIOPRED TranSMART 275 
database. Due to the exploratory nature of this study, unadjusted p-values were used and p-276 
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values <0.05 were considered significant using the Kruskal-Wallis-, Mann-Whitney U- or 277 
Chisq-test.  Extreme value analysis was performed using R (v3.4.4, CRAN Network) and 278 
statistical evaluation in GraphPad Prism (v8, GraphPad).  Multivariate correlation analysis 279 
between variables used to calculate the RASP (Refractory Asthma Stratification Program) T2 280 
severity score (blood eosinophils, FENO, and serum periostin (21)), and the three urinary 281 
metabolites of interest (LTE4, tetranorPGDM, and 2,3-dinor-11β-PGF2α) was performed 282 
using partial least squares (PLS) regression.  The correlation between the two data blocks 283 
(inner relation) was calculated as the Pearson’s r between the resulting latent variables as 284 
previously described (22), with p <0.05 considered significant.  285 
 286 
  287 
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Results  288 
Urinary excretion of eicosanoid metabolites in healthy participants 289 
The highest urinary levels were those of the main metabolite of PGE2, tetranorPGEM (Figure 290 
2, Table 3), which was the only metabolite to display meaningful sex differences with 291 
median values among men being approximately twice those of women (men 1510 vs. women 292 
701 ng/mmol creatinine; p<0.01; Figure 2, Table 3). 293 
Isoprostanes constituted the second most abundant group of metabolites (Figure 2, 294 
Table 3).  The median levels of 8,12-iso-iPF2α-VI were highest, followed by 2,3-dinor-8-iso-295 
PGF2α, whereas the commonly measured 8-iso-PGF2α was the least abundant, accounting for 296 
only ~4% of total isoprostane levels.  There was a small sex difference for the median levels 297 
of 2,3-dinor-8-iso-PGF2α (151 for men vs. 214 ng/mmol creatinine for women; p<0.05). 298 
The two major metabolites of PGD2, tetranorPGDM and 2,3-dinor-11β-PGF2α, were 299 
found in a similar range as the two 8-iso-IPs (Figure 2, Table 3).  The panel did not include 300 
downstream metabolites of PGF2α, but the parent compound was consistently detected at 301 
concentrations ~10-fold higher than those of primary PGE2 (Figure 2, Table 3).  302 
Concentrations of the sequential metabolites of TXA2, 11-dehydro-TXB2 and 2,3-dinor-303 
TXB2, were similar in abundance as PGE2, but less than PGF2α (Figure 2, Table 3).  The 304 
least abundant analyte was the terminal metabolite of the CysLTs, LTE4 (median 305 
concentration 3.1 ng/mmol creatinine) (Figure 2, Table 3). 306 
None of the eicosanoid metabolites in healthy participants showed biologically 307 
meaningful correlations with age or BMI (data not shown).  In addition, except for the 308 
metabolites mentioned above, there were no concentration differences in relation to sex.   309 
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Comparison of concentrations between the study groups 310 
For five of the six pathways quantified (PGD2, PGF2α, TXA2, isoprostanes and CysLTs), 311 
there was a general pattern of progressively higher concentrations from healthy to severe 312 
asthma; group median levels in mild-to-moderate asthmatics were higher compared with 313 
healthy participants, and further elevations were evident in severe asthma in comparison with 314 
mild-to-moderate (Figure 3, Table 3).  The observed levels occasionally reached statistical 315 
significance between healthy participants, mild-to-moderate asthmatics and the two severe 316 
asthma groups, and primarily between healthy participants and either or both of the severe 317 
asthma groups.  318 
The levels of LTE4 were significantly higher in all asthma groups relative to healthy 319 
participants, with the strongest difference for LTE4 (median fold change (MFC) ≥2.0, 320 
p<0.0001) in either severe asthma group (Figure 3d, Table 3).  The PGD2 metabolites 321 
(tetranorPGDM and 2,3-dinor-11β-PGF2α) were also elevated in relation to asthma severity 322 
(healthy participants vs. either severe asthma group, MFC≥1.4, p<0.001; healthy participants 323 
vs. either severe asthma group, MFC≥1.3, p<0.001; respectively) (Figure 3a-b, Table 3). 324 
Two isoprostanes (8-iso-PGF2α and 2,3-dinor-8-iso-PGF2α) were significantly 325 
elevated in the severe asthma group, with 8-iso-PGF2α additionally showing a linear increase 326 
with asthma severity.  The increase in 8-iso-PGF2α was to a great extent driven by the 327 
women, a trend also shown for its metabolite 2,3-dinor-8-iso-PGF2α (Table E1 in the Online 328 
Data Supplement).  The median level of the most abundant isoprostane, 8,12-iso-iPF2α-VI, 329 
was however the same in all four study groups (Figure 3g-i, Table 3). 330 
In distinct contrast to the other metabolites, primary PGE2 was lower in mild-to-331 
moderate asthmatics than in healthy participants, but reached higher levels in severe asthma 332 
compared to healthy participants (Figure 3j).  Moreover, in men, the main tetranorPGEM 333 
was also lower in mild-to-moderate asthmatics than in healthy participants, and its levels in 334 
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either of the severe asthma groups were no different from that of healthy participants (Figure 335 
3k, Table 3).  The same numerical trends were observed for tetranorPGEM in women, 336 
although only smoking asthmatics were statistically different from healthy participants.  337 
Among both women and men, smoking severe asthmatics had higher levels of tetranorPGEM 338 
than the corresponding non-smokers. 339 
Influence of oral corticosteroid (OCS) treatment 340 
The use of prescribed OCS was similar in severe asthmatic smokers and non-smokers (40% 341 
and 41%, respectively; Table 1), with the vast majority receiving daily treatment (122 of 124 342 
non-smokers and 43 of 44 smokers).  However, for 9 of the 11 measured metabolites, there 343 
were no differences in the concentrations in urine between asthmatics reporting taking OCS 344 
and those stating no use (Table 4).  The exceptions were 2,3-dinor-TXB2 and 8,12-iso-iPF2α-345 
VI, both of which exhibited slightly lower levels (12-13%) among the subjects prescribed 346 
OCS. 347 
The virtual absence of steroid influence on urinary eicosanoid metabolite 348 
concentrations was strengthened when the prescription information was combined with data 349 
on the actual detection of prednisone metabolites in urine (Table 4).  Stratifying subjects 350 
according to this stricter classification again demonstrated no differences between groups for 351 
the majority of measured metabolites in the severe asthma subjects.  The observed lower 352 
levels of the same two metabolites (2,3-dinor-TXB2 13% lower and 8,12-iso-iPF2α-VI 20% 353 
lower) were replicated in this smaller, but objectively verified group of OCS users (Figure 354 
4a).  Consistent with the overall findings, there were no signs of dose-related effects of 355 
steroid treatment on urinary levels of CysLTs or PGD2-metabolites when adult (U-356 
BIOPRED) and adolescent (Swedish Search, see below) subjects were subdivided into three 357 
urine prednisolone concentration groups or by three budesonide dose groups, respectively 358 
(Figures 4b-c).   359 
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Relation between eicosanoid metabolites and omalizumab treatment 360 
In view of the report that omalizumab treatment may decrease the levels of urinary LTE4 and 361 
metabolites of PGD2 (23), we performed a sub-group analysis of 52 severe asthmatics on 362 
omalizumab treatment in the year before the study.  The serum IgE levels were matched 363 
using a (1:2) case-control design with no difference in standard asthma medication usage, 364 
including OCS and ICS, anti-leukotriene or long acting B2-agonist (LABA) (Table E2 in the 365 
Online Data Supplement).  The omalizumab group had lower levels of the early PGD2 366 
metabolite 2,3-dinor-11β-PGF2α (p<0.05), LTE4 (p<0.01) and 11-dehydro-TXB2 (p<0.01), 367 
with a tendency of fewer high values in this group (Figure 5, Table E3 in the Online Data 368 
Supplement).  There were no other group differences with respect to common T2 markers, 369 
including blood eosinophils, serum periostin or FENO (Table E2 in the Online Data 370 
Supplement). 371 
Extreme value analysis in U-BIOPRED 372 
The majority of the monitored eicosanoid pathways evidenced progressive increases with 373 
asthma severity, but also showed considerable overlap between the study groups (Figure 3).  374 
We therefore further stratified the asthmatics according to high (75th) and low (25th) 375 
percentile distribution for each eicosanoid pathway in order to identify associations between 376 
urinary metabolite levels and clinical outcomes as well as other biomarkers. 377 
The most prominent associations in this extreme group comparison were found between 378 
high urinary LTE4 and low lung function as well as typical T2 inflammation markers such as 379 
FENO, blood and sputum eosinophils, serum periostin and IL-13 (Figure 6).  In addition, 380 
high urinary LTE4 showed a significant association with high serum IgE, as with the T2 381 
associated CCL-18 (Table E4 in the Online Data Supplement).  A number of other serum 382 
markers were higher in the high LTE4 group including: CCL-26 (eotaxin-3), CCL-17 383 
(TARC), MMP-3, IL-1α, and TNFα (Table E4 in the Online Data Supplement). 384 
12 
 
The pattern of high composite PGD2 metabolites (c-PGD2) was similar to the T2 profile 385 
and the low lung function associated with high LTE4 (Figure 6), although values for FENO 386 
and serum periostin did not reach significance.  Higher urinary c-PGD2 was also associated 387 
with poorer ACQ-5 and AQLQ scores and higher CRP, but greater reversibility.  The high 388 
urinary PGD2 metabolite group displayed greater levels of several cytokines including CCL-389 
18 (Table E4 in the Online Data Supplement).  The subjects in the groups with high LTE4 or 390 
high composite PGD2 received OCS more frequently, along with more frequent detection of 391 
urinary OCS.  However, the high LTE4 and c-PGD2 groups were comprised of more subjects 392 
with severe asthma (Table E5 in the Online Data Supplement).  393 
The high isoprostane group (c-isoprostanes) included more women (81% vs. 40% in the 394 
low isoprostane group), higher BMI, higher hsCRP, more frequent exacerbations, poorer 395 
results in ACQ-5, AQLQ, and HADS, but lower FENO (Table E4-5 in the Online Data 396 
Supplement).  High values for tetranorPGEM in women related to low lung function, but not 397 
the sets of typical T2 markers (Table E4 in the Online Data Supplement).  In men, the 398 
variability of this metabolite was greater and there were only a few associations with serum 399 
proteins (Table E4 in the Online Data Supplement).  400 
Internal validation of U-BIOPRED findings at 12 to 18-months follow-up  401 
Samples from 302 (73.5 %) of the severe asthmatics were employed as an internal validation 402 
to test the observed relationship between baseline between urinary LTE4 and metabolites of 403 
PGD2, and the T2 markers.  The main clinical outcomes did not change at the longitudinal 404 
timepoint, including the incidence of OCS treatment (Table 5).  The primary findings were 405 
confirmed, demonstrating the temporal stability of the eicosanoid T2 signature (Table 5).  406 
For LTE4, >95% of the subjects had values within 1 SD between the two time-points, while 407 
for the PGD2 metabolites, this measure was only slightly less (87.4 %) (Table E6 in the 408 
Online Data Supplement).  Moreover, repeating the extreme value analysis confirmed that 409 
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high urinary LTE4 and c-PGD2 were significantly associated with blood and sputum 410 
eosinophils and serum IL-13 at the longitudinal visit (Figure 6).  A nominal decrease in 411 
FEV1(%) was observed for both LTE4 and c-PGD2 high subjects, while FENO and serum 412 
periostin were strongly elevated in the LTE4 high group, but not in the c-PGD2 high group.   413 
External validation of U-BIOPRED findings in the adolescent Swedish Search cohort 414 
In this external validation cohort of 57 school-aged subjects with severe asthma and 38 415 
subjects with controlled persistent asthma, there were significant differences in clinical 416 
outcomes at the group level (Table 2).  However, the median levels of urinary CysLTs and 417 
PGD2-metabolites as well as the eosinophil marker EDN were not different between the two 418 
study groups (Table 2).  In contrast, performing the same extreme group comparison as U-419 
BIOPRED uncovered clinically meaningful differences between subjects allocated to the high 420 
and low quartiles for urinary levels of CysLTs and PGD2-metabolites (Figure 7 and Table 421 
E7 in the Online Data Supplement).  The high level groups displayed the same associations 422 
with lower FEV1(%) and elevated T2 markers (e.g., blood eosinophils, serum IgE and urinary 423 
EDN - a surrogate marker for eosinophil activation (24)) as in the U-BIOPRED study.  In 424 
addition, the high LTE4 and PGD2-metabolite groups had increased methacholine 425 
responsiveness (Table E7).  There was a numerical, albeit small, increase in FENO, whereas 426 
serum periostin levels were not different (Figure 6, Table E7 in the Online Data 427 
Supplement).  There was no treatment bias between the groups (Table E7 in the Online Data 428 
Supplement).   429 
Comparison of urinary LTE4 and PGD2 metabolites with established T2 markers 430 
In order to determine the performance of urinary eicosanoids as markers for T2 asthma, LTE4 431 
and PGD2-metabolites were benchmarked against established markers.  First, we constructed 432 
a heat-map where each cell represented the percent overlap between two compared 433 
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biomarkers (Figure 8).  Cutoffs for blood eosinophils, FENO, periostin, and serum IgE were 434 
selected from previous work in U-BIOPRED and other consortia (21), and the data in the 435 
healthy participants group was used to define high LTE4 and c-PGD2 (see figure legend).  436 
Generally, T2 cutoffs identified similar percentages of individuals with high LTE4, blood 437 
eosinophils and FENO, while the percentages were slightly lower for periostin and IgE 438 
(Figure 8a).  Urinary c-PGD2 showed slightly less overlap with the other selected markers, 439 
but high interrelation with LTE4.  The same relationships were observed for the severe 440 
asthma group at the 12-18-month longitudinal visit (Figure 8b). 441 
Next, multivariate correlation analysis was preformed between the latent variable 442 
representing the levels of the markers used to calculate the RASP T2 score (blood 443 
eosinophils, FENO, and periostin (21)) and the latent variable representing the concentrations 444 
of three urinary metabolites (LTE4, tetranorPGDM, and 2,3-dinor-11β-PGF2α).  The RASP 445 
score combines blood eosinophils, FENO, and serum periostin values into one digit (2= high; 446 
1= intermediate; 0 = low).  Complete data sets were obtained for 364 of the asthmatics at the 447 
baseline visit (Table E5), and for 202 of the severe asthmatics that attended the follow-up 448 
visit.  The correlation for subjects with a high RASP score was significant across all U-449 
BIOPRED asthma groups both at baseline (Figure 9a; n=112, r=45, p<0.00001) and at the 450 
longitudinal follow-up (Figure 9b; n=52, r=0.48, p=0.0003).  In contrast, the correlation for 451 
subjects with an intermediate (Figure 9c; n=200, r=0.20) or low (Figure 9d; n=75, r=0.22) 452 
RASP score displayed essentially no relevant correlation with the urinary eicosanoids, as 453 
evidenced by the flat slopes (y=0.04x).  Taken together, the findings demonstrate a strong 454 










This report presents the largest data set to date on urinary lipid mediator metabolites in 461 
subjects with asthma.  The results were obtained with a new analytical platform specifically 462 
designed for the U-BIOPRED study (20).  The selected 11 urinary eicosanoid metabolites 463 
monitored six major pathways (Figure 1) in samples from 597 individuals, of whom 100 464 
were healthy participants providing an estimation of reference values.  It was discovered that 465 
high urinary levels of LTE4 and the main PGD2 metabolites were associated with asthma 466 
severity and markers of T2 airway inflammation.  The finding was internally validated in a 467 
follow-up study of 302 of the adult severe asthmatics 12-18 months after the original study as 468 
well as externally validated in an adolescent population with asthma.  Moreover, in both 469 
cohorts, we show that the urinary levels of eicosanoid metabolites were unrelated to the 470 
degree of treatment with inhaled or oral glucocorticosteroids, substantiating findings in 471 
previous smaller studies suggesting that steroids do not affect eicosanoid biosynthesis in vivo.   472 
Our previous studies have shown that measurements of urinary eicosanoids in association 473 
with bronchial challenges can elucidate mediator mechanisms (13, 14, 25).  There are three 474 
main explanations of why the excretion of urinary eicosanoid metabolites reflects inflammatory 475 
processes in the airways.  First, eicosanoids are a dynamic class of mediators with rapid turn-476 
over from the biosynthesis of the biologically active substances in immune-competent and 477 
structural cells of the airway tissue to the excretion of inactive metabolites in the urine.  478 
Second, the airway mucosa is highly perfused with a large total surface area.  Inflammatory 479 
reactions in the lower respiratory tract that stimulate the biosynthesis of a particular eicosanoid 480 
will therefore rapidly be mirrored in blood and almost immediately reflected by the appearance 481 
of these metabolites in the urine.  In contrast, local inflammatory reactions in mucosal tissues 482 
with less surface area, such as the nasal airways, do not lead to distinguishable changes in 483 
urinary eicosanoid levels (26).  Third, the source of eicosanoid metabolites in urine may be 484 
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interpreted with considerable confidence by considering the physiological context.  For 485 
example, in subjects with ischemic heart disease, increased urinary excretion of metabolites of 486 
TXA2 reflects ongoing platelet activation (27).  Likewise, in systemic mastocytosis (28), the 487 
levels of the urinary PGD2 metabolites and the major histamine metabolite are increased 488 
because of an extra-pulmonary supply.  In the context of asthma, multiple studies with repeated 489 
urine sampling during bronchoprovocations with allergen, exercise, or aspirin (in subjects with 490 
aspirin-intolerant asthma) have consistently documented increased levels of LTE4 and PGD2 491 
metabolites in the urine in correlation with the induced airflow obstruction (9, 14, 25).  492 
Initially, normal values for the urinary eicosanoids were established in the 100 healthy 493 
participants (Figure 2).  The observed concentrations ranged from a few ng/mmol creatinine 494 
for LTE4 to thousands of ng/mmol creatinine for the most abundant metabolite tetranorPGEM 495 
(Figure 2 and Table 3).  Although levels of the isoprostane 2,3-dinor-8-iso-PGF2α and 2,3-496 
dinor-TXB2 were somewhat higher in women, the only pronounced sex difference was for 497 
tetranorPGEM, where men had about twice the levels of women.  The higher concentration of 498 
tetranorPGEM in men confirm previous findings in smaller studies (25, 29) and likely reflects 499 
a high level of biosynthesis in male accessory genital glands. 500 
Next, eicosanoid levels were evaluated in the asthmatic groups.  A progressive increase 501 
was observed in most eicosanoid metabolites from healthy participants to asthmatics, and in 502 
relation to asthma severity.  This trend was particularly significant for LTE4 and the two PGD2 503 
metabolites, but also for metabolites of TXA2 originating from platelets, in keeping with 504 
suggestions of enhanced platelet activation in asthma (30).  Whereas the biosynthesis of PGD2 505 
in humans occurs predominantly in mast cells, CysLTs are generated by activated mast cells 506 
and eosinophils, as well as in transcellular interactions (31).  507 
The one exception to the general trend for higher levels of urinary eicosanoid metabolites 508 
in asthma was tetranorPGEM, which evidenced significantly lower median levels in men with 509 
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mild-to-moderate asthma and a similar, albeit nonsignificant, decrease in women.  The levels of 510 
tetranorPGEM were often numerically lower in non-smoking asthmatics (both mild and severe) 511 
than in healthy participants.  Because PGE2 has anti-asthmatic effects including stabilization of 512 
mast cells and inhibition of ILC2 cells (32–34), it could be speculated that decreased 513 
production of PGE2 in the airways might be one of several deficiencies associated with asthma. 514 
One confounding factor in biomarker studies is that treatment with corticosteroids may 515 
modulate observed levels.  This large study however documents that the majority of urinary 516 
eicosanoid metabolites were unaffected by steroid use, whether following stratification of 517 
patients by historical prescription of OCS or by objectively quantifying metabolites of urinary 518 
prednisone.  The latter approach has, to the best of our knowledge, not been used previously in 519 
studies of eicosanoid metabolites in urine.  The slightly lower (10-20%) values of 2,3-dinor-520 
TXB2 and 8,12-iso-iPF2α-VI in OCS users warrant replication in an interventional trial, but 521 
appear to be relatively unimportant.  The same responses were observed in the adolescent 522 
subjects, where no significant change in urinary PGD2-metabolites or CysLT was observed in 523 
relation to the ICS dose of budesonide.  Our findings therefore confirm and extend previous 524 
data from smaller studies indicating that the biosynthesis of prostaglandins and CysLTs are not 525 
affected by corticosteroids (35–39).  These observations in turn provide the rational for add-on 526 
treatments with anti-leukotrienes and other drugs that target specific eicosanoids. 527 
Anti-IgE treatment is another therapeutic modality targeting T2 inflammation.  In U-528 
BIOPRED, 52 of the severe asthmatics had been prescribed omalizumab.  We therefore 529 
performed a case-control sub-study, which found that the levels of LTE4 and metabolites of 530 
PGD2 and TXA2 were lower in the omalizumab group compared with matched control patients.  531 
These associations agree with a previously published open label study (23) that recently was 532 
confirmed in a controlled trial (40).  Interestingly, in the controlled study, the effect on basal 533 
excretion of LTE4 and tetranorPGDM was of the same order of magnitude as the difference we 534 
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here report between the omalizumab group and the matched controls in U-BIOPRED.  For 535 
example, we found 30% lower values for LTE4 and they reported a 21% reduction after 3 536 
months of treatment.  537 
While levels of most urinary eicosanoids were broadly related to the presence of 538 
disease and its severity, significant overlap was observed across the groups (Figure 3).  In 539 
order to more clearly identify associations between high levels of urinary eicosanoids and 540 
other asthma biomarkers, as well as clinical outcomes, an extreme group analysis of the data 541 
was performed.  The consistent finding was that high levels (i.e., upper quartile) of LTE4 in 542 
particular, but also of composite PGD2 metabolites, strongly associated with T2 biomarkers 543 
including blood and sputum eosinophils, serum periostin and IL-13, as well as high FENO.  544 
The subjects with the highest levels of urinary LTE4 and composite PGD2 metabolites also 545 
had worse lung function (FEV1 64% and 67% predicted vs. 76% and 77% in the patients in 546 
the lowest quartiles for these two metabolites; Figure 6).  The lower lung function associated 547 
with elevated levels of the two eicosanoids presumably relates to the fact that both 548 
compounds are potent mediators of airway obstruction.   549 
The strength of the discovered T2 association was first validated internally at the 550 
longitudinal visit, lending evidence to the existence of a stable biochemical and physiological 551 
T2 association.  The long-term stability of profiles and levels of urinary eicosanoid 552 
metabolites in individuals has not been studied extensively.  The results of the longitudinal 553 
follow-up 12 to 18-month after the baseline visit however demonstrated preserved excretion 554 
of high levels of urinary LTE4 and tetranorPGDM in the severe asthmatics.  This observation 555 
is in line with some treatment trials with 5-LOX inhibitors, suggesting that the fluctuations of 556 
urinary LTE4 in the placebo arms are modest (8, 41, 42).  There is recent data for 8-iso-PGF2α 557 
and tetranorPGEM that document excellent stability over five months (43), and the recent 558 
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controlled trial of omalizumab in subjects with aspirin-exacerbated respiratory disease 559 
(AERD) showed no variability during the placebo period (40).   560 
As atopy and T2 inflammation generally are more common in pediatric asthma, the T2 561 
associations from U-BIOPRED were then externally validated in urine samples from an 562 
independent cohort of school-children with severe or controlled persistent asthma. All 563 
included T2 markers were significantly associated with urinary LTE4 and PGD2-metabolites 564 
in the adolescent cohort, except for FENO and periostin (Figure 7).  While nominal FENO 565 
levels were higher, they did not reach significance and serum periostin levels are not a useful 566 
T2 marker in children due to bone growth (44).  The eosinophil activation marker urinary 567 
EDN was used in the extreme value analysis because sputum eosinophils were not available 568 
from the adolescent cohort, and the data suggest that this protein would be a useful 569 
component of a urinary T2 phenotyping panel.   570 
The utility of urinary LTE4 and PGD2 metabolites to identify the T2 endotype was 571 
compared to the more traditional markers in an exploratory post-hoc analysis (Figures 8-9).  572 
For this benchmarking screen, we used cutoffs for the current markers that are commonly 573 
applied in other studies including U-BIOPRED (21).  The cutoff values for LTE4 and c-PGD2 574 
were defined by the baseline excretion levels in the healthy participants group of U-BIOPRED.  575 
Generally, a majority of subjects above each T2 biomarker cutoff presented elevated blood 576 
eosinophils and urinary LTE4 to a similar degree, and were closely followed by FENO, serum 577 
periostin and serum IgE, and with fewer subjects having high c-PGD2 (Figure 8).  Moreover, a 578 
multivariate analysis approach to benchmarking the urinary eicosanoids provided similar 579 
findings (Figure 9).  In this case, the three RASP markers (blood eosinophils, FENO, and 580 
periostin) were combined into a single latent variable and compared with a combined latent 581 
variable for the urinary eicosanoids (LTE4, tetranorPGDM, and 2,3-dinor-11β-PGF2α).  582 
Asthmatics with a high RASP score, indicating a high T2 phenotype, correlated strongly with 583 
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the urinary eicosanoid levels at both baseline and at the longitudinal follow-up.  In contrast, 584 
subjects with an intermediate or low RASP score displayed no relevant correlation.  The 585 
findings collectively further support the exploration of urinary LTE4 and PGD2-metabolites as 586 
non-invasive biomarkers of T2 inflammation. The use of eicosanoids as biomarkers should also 587 
be considered within the context that they are known biologically active mediators of 588 
inflammation and sensitive markers of select activation of key immune cells, especially 589 
eosinophils and mast cells.  It is therefore warranted to test the use of urinary eicosanoids for 590 
stratification of patients for treatment with biologics that target T2 inflammation (e.g., anti-591 
IL-5s, anti-IL4Rα and anti-alarmins).   592 
In contrast to the T2 asthma associations for PGD2 and the CysLTs, high isoprostane 593 
levels were associated with a different phenotypic pattern.  This group was enriched in women 594 
with high BMI, lower FENO, poor quality of life (AQLQ), more frequent exacerbations, 595 
elevated hsCRP, and worse asthma control.  This observation suggests a role for isoprostanes as 596 
markers of a non-T2 phenotype, presumably the phenotype of asthma dominated by women 597 
with high BMI.  The isoprostane 8-iso-PGF2α, is in particular considered to be a gold standard 598 
as a marker of oxidative stress (45), which is at least partially due to the availability of an 599 
immunoassay.  However, in the current study, the mass spectrometry-based quantification of 8-600 
iso-PGF2α accounted for <5% of the total observed isoprostane metabolites in the urine.  601 
Interestingly, 8-iso-PGF2α exhibited a significant increase with asthma severity (Figure 3g), 602 
while the more abundant metabolites 2,3-dinor-8-iso-PGF2α and 8,12-iso-iPF2α-VI had weaker 603 
responses.  Future studies are needed to clarify the biological indications of these species, 604 
including a screen of all 64 potential isoprostanes and their metabolites in urine (12), to 605 
determine the most appropriate analyte to serve as a marker of oxidative stress. 606 
One limitation of the study was that levels of PGI2 metabolites were lost because of 607 
technical problems, and the PGF2α pathway was only assessed by the parent compound.  The 608 
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latter shortcoming has been mitigated in our updated version of the platform that includes 609 
downstream metabolites of PGF2α (15).  Although the stability of the key eicosanoid 610 
metabolites was demonstrated at 12-18 months follow-up, there is a need for further studies of 611 
the long-term fluctuations of eicosanoid metabolites in urine in both health and disease.  There is 612 
also emerging evidence suggesting that defective biosynthesis of specialized pro-resolving 613 
mediators (46) may be part of the severe asthma pathobiology (47).  However, the in vivo 614 
metabolism of these mediators remains to further determined (48) before indicative markers 615 
may be followed in the urine. 616 
We conclude that this study supports the premise that asthma phenotyping may be aided 617 
by measurements of indicative metabolites of lipid mediators in the urine.  The discovery of 618 
strong associations between urinary LTE4, PGD2-metabolites and markers of T2 inflammation 619 
warrant application in future treatment trials with biologics, and strengthen the key role of mast 620 
cells and eosinophils in asthma.  Urinary eicosanoid signatures could be particularly useful to 621 
guide selection for treatment in children with severe asthma in whom sputum induction and 622 
blood sampling can be challenging.  The panel of urinary biomarkers could potentially be 623 
enhanced by standardized inclusion of non-eicosanoid markers, for example histamine 624 
metabolites (49) and EDN (24).  Due to its non-invasive nature, the measurement of urinary 625 
eicosanoids would be particularly useful at the point of primary care where the vast majority of 626 
asthma patients are managed. 627 
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Figure legends 788 
Figure 1.  Schematic overview of arachidonic acid-derived lipid mediators (eicosanoids) 789 
following both enzymatic and non-enzymatic metabolism.  Blue text indicates the known or 790 
proposed biological effect of the indicated pathway.  Grey boxes highlight eicosanoids 791 
quantified in urine from participants in the U-BIOPRED study by ultra-performance liquid 792 
chromatography tandem mass spectrometry (UPLC-MS/MS).  Enzyme nomenclature is 793 
defined according to the following: cytosolic phospholipase A2 (cPLA2), five lipoxygenase-794 
activating protein (FLAP), 5-lipoxygenase (5-LOX), cyclooxygenase (COX), prostaglandin 795 
E-synthase (PGES), prostaglandin D-synthase (PGDS), prostaglandin F-synthase (PGFS), 796 
prostaglandin I-synthase (PGIS) and thromboxane A-synthase (TXAS). 797 
 798 
 799 
Figure 2.  Median (IQR) urinary concentration of individual eicosanoids in the adult baseline 800 
healthy participant (HC) group (n=100).  TetranorPGEM concentrations are stratified by sex. 801 
Eicosanoid abbreviations are defined according to the following: prostaglandin (PG), 802 
thromboxane (TX) and cysteinyl-leukotriene (CysLT).  IQR = inter quartile range. 803 
 804 
 805 
Figure 3.  Distribution of urinary eicosanoid concentrations in healthy participants (HC, 806 
n=100), mild-to-moderate asthmatics (MMA, n=86), severe asthma non-smokers (SAn, 807 
n=302) and severe asthma smokers or ex-smokers (SAs/ex, n=109) group.  Data is plotted on 808 
a log2-scale.  Boxes highlight the interquartile range (IQR) with group median, bars display 809 
the total distribution range (min to max).  Significant group differences are indicated by p-810 
value determined by the Mann-Whitney U-test. 811 
 812 
 813 
Figure 4.  Effect of oral corticosteroids (OCS) upon observed urinary eicosanoid levels.  (a)  814 
Stratification of adult U-BIOPRED subjects with severe asthma according to reported use of 815 
OCS and whether prednisolone or prednisolone metabolites were detected in urine (OCS; 816 
n=90 or no OCS; n=167) (Data from Table 5b).  (b) Median (IQR) of urinary LTE4, 817 
tetranorPGDM and 2,3-dinor-11β-PGF2α concentrations across subjects with detectable 818 
urinary prednisolone in the adult U-BIOPRED study.  Quantified urinary prednisolone is 819 
stratified into: <500 (n=17), 500-200 (n=27) and >2000 ng/mL (n=24).  (c) Median (IQR) of 820 
urinary concentration of CysLT and PGD2 metabolites across the three inhaled corticosteroid 821 
budesonide dose groups in adolescent children from the Swedish Search study.  Budesonide 822 
is stratified into: <500 (n=38), 500-200 (n=46) and >2000 ng/mL (n=11).  IQR = inter 823 
quartile range. 824 
 825 
 826 
Figure 5.  Severe asthma subjects from the adult U-BIOPRED study with a history of 827 
omalizumab treatment (n=52) were compared in a case-control design (1:2) to a group 828 
(n=104) matched for similarities in serum IgE.  The violin plot horizontal lines correspond to 829 
group median and IQR values for the two PGD2 metabolites and LTE4.  Group comparisons 830 
were evaluated by the Mann-Whitney U-test.  (Data from Table E4 in the Online Data 831 







Figure 6.  Selection of U-BIOPRED adult asthmatic participants with mild-to-moderate 837 
asthma (MMA), severe asthma non-smokers (SAn) and smokers/ex-smokers (SAs/ex) at 838 
baseline using the 25th and 75th concentration percentile of urinary LTE4 and calculated 839 
composite (log2-transformed and z-scored) variables for PGD2-metabolites (c-PGD2).  A 840 
complete list of significant associations is provided in Table E6 in the Online Data 841 
Supplement.  At the 12 to 18-month follow-up visit (longitudinal), 302 subjects with severe 842 
asthma were used for internal validation of the T2 associations.  Data presented as median 843 
(IQR) and evaluated by Mann-Whitney U-test.  IQR = inter quartile range. 844 
 845 
 846 
Figure 7.  Validation of adult T2 associations in adolescent subjects from the Swedish Search 847 
study.  Severe or controlled persistent asthmatics were stratified using the 25th and 75th 848 
concentration percentile of urinary metabolites of *PGD2 and CysLTs.  For each percentile, 849 
the corresponding variable group median (IQR) differences were evaluated by the Mann-850 
Whitney U-test. (*) Total urinary PGD2-metabolites were determined by EIA, which has a 851 
9:1 binding ratio towards 2,3-dinor-11β-PGF2α:11β-PGF2α as determined by a cross-reactivity 852 
test and LC-MS/MS (9).  IQR = inter quartile range. 853 
 854 
 855 
Figure 8.  Relationship between proposed T2 markers (a) at baseline and (b) at the 12- to 18-856 
month longitudinal follow-up visit.  The heat-map displays the percentage overlap between 857 
high levels of four common T2 markers and the two urinary eicosanoid markers LTE4 and c-858 
PGD2.  Established cutoffs (21) for the T2 markers were used (blood eosinophils 300 859 
counts/µL, FENO 30 ppb, periostin 55 ng/mL and IgE 150 IU/mL).  Cutoff values for the 860 
urinary metabolites were calculated from median+1SD in the healthy control group (Table 861 
3).  Each cell represents the percentage of subjects satisfying both cutoffs for a given 862 
comparison.  For example, see first row in Figure 8a, 62% of the n=195 subjects with blood 863 
eosinophils 300 counts/µL also have urinary LTE4 6.4 ng/mmol creatinine.  The total 864 
number of subjects positive for each row-criterion is displayed in the far right column.  865 
Serum IgE data were only available at baseline.  c-PGD2 is a z-scored composite variable 866 
consisting of tetranorPGDM and 2,3-dinor-11β-PGF2α (see Methods). 867 
 868 
 869 
Figure 9.  Multivariate correlation analysis between the latent variable consisting of the 870 
markers employed to calculate the RASP T2 severity score (blood eosinophils, FENO, and 871 
serum periostin, (21)), and the latent variable representing concentrations of the three urinary 872 
eicosanoid metabolites LTE4, tetranorPGDM, and 2,3-dinor-11β-PGF2α.  The correlation for 873 
subjects with a high RASP score with urinary eicosanoid concentrations was significant 874 
across all U-BIOPRED asthma groups both at (a) baseline (n=112) and at (b) the longitudinal 875 
follow-up (n=52).  In contrast, the correlation for baseline subjects with a (c) intermediate 876 
(n=200) or (d) low (n=75) RASP score displayed no relevant correlation with the urinary 877 
eicosanoid levels, as evidenced by the flat slopes (y=0.04x).  MMA= mild-to-moderate 878 
asthma, SAn= severe asthma nonsmokers, and SAs/ex= severe asthma smokers or ex-879 
smokers, r = Pearson’s inner relation correlation coefficient, RASP= refractory asthma 880 
stratification program, B-eos= blood eosinophils, PGD2-metabolites = tetranorPGDM and 881 






Table 1. U-BIOPRED study characteristics of 597 subjects used for urinary eicosanoid metabolite profiling. 886 











Subjects (n) 100 - 86 - 302 - 109 - - 
Age (years)  35 (27-49) (n=100) 43 (28-53) (n=86) 53 (43-62) (n=302) 55 (48-61) (n=109) <0.0001 
Sex (% female) 39% - 50% - 66% - 51% - <0.0001 
BMI (kg/m2) 24.6 (22.8-27.5) (n=100) 24.8 (23.1-28.8) (n=86) 27.8 (24.6-33.7) (n=302) 28.9 (25.2-32.6) (n=109) <0.0001 
FEV1 (%) 102 (94-110) (n=100) 92 (76-100) (n=85) 67 (51-85) (n=299) 66 (53-78) (n=109) <0.0001 
Exacerbations (n) NA - 0.0 (0-1.0) (n=86) 2.0 (1.0-3.0) (n=301) 2.0 (1.0-4.0) (n=109) <0.0001 
Smoking history (pack-years) 1 (0−4) (n=20) 4 (1-5) (n=13) 2 (1-4) (n=43) 17 (10−26) (n=109) <0.0001 
ACQ-5 NA - 0.8 (0.3-1.4) (n=83) 2.2 (1.4-3.0) (n=291) 2.2 (1.4-3.0) (n=106) <0.0001 
AQLQ NA - 6.2 (5.4-6.5) (n=82) 4.6 (3.6-5.4) (n=299) 4.4 (3.5-5.3) (n=105) <0.0001 
Daily to weekly OCS use NA - NA - 41% (n=124) 40% (n=44) - 
OCS (mg eq.) NA - NA - 12 (8-20) (n=145) 16 (10-25) (n=58) 0.1374 
Omalizumab users NA - NA - 13% (n=40) 13% (n=14) - 
Comb. atopy (% positive) 40%  (n=40) 90%  (n=77) 74% (n=224) 62% (n=68) <0.0001 
FENO (ppb) 19 (13-29) (n=95) 25 (18-52) (n=85) 27 (16-48) (n=281) 23 (12-43) (n=103) 0.0005 
Periostin (ng/mL) 50 (44-57) (n=88) 49 (41-55) (n=71) 50 (42-60) (n=250) 44 (36-59) (n=85) 0.0339 
Sputum-eosinophils (%) 0.3 (0.2-0.9) (n=18) 1.3 (0.7-3.9) (n=35) 4.1 (1.3-26.5) (n=109) 4.5 (1.1-13.8) (n=49) <0.0001 
Blood-eosinophils (counts/µL) 100 (90-200) (n=100) 200 (100-300) (n=86) 200 (100-400) (n=294) 220 (110-405) (n=105) <0.0001 
Serum IL-13 (pg/mL) 0.4 (0.3-0.6) (n=87) 0.6 (0.4-0.9) (n=70) 0.6 (0.3-1.1) (n=245) 0.5 (0.3-1.1) (n=82) 0.0004 
Serum total IgE (IU/mL) 23 (9-63) (n=97) 89 (50-244) (n=83) 119 (45-347) (n=295) 124 (59-343) (n=106) <0.0001 
hsCRP (mg/L) 0.8 (0.3-1.6) (n=97) 0.8 (0.4-2.1) (n=85) 2.1 (0.9-4.9) (n=295) 2.3 (1.1-4.8) (n=109) <0.0001 
Data are presented as median (interquartile range, IQR), % (actual number).  Significance was evaluated using a Kruskal-Wallis nonparametric test or Chisq 887 
for categorical variables. Body mass index (BMI), forced expiratory volume in 1 s pre-bronchodilator (FEV1%), forced vital capacity (FVC), asthma control 888 
questionnaire mean of 1-5 (ACQ-5), asthma quality of life questionnaire total mean (AQLQ), fractional exhaled nitric oxide (FENO), inhaled corticosteroids 889 
(ICS) in µg fluticasone proprionate/day or equivalent, high sensitivity c-reactive protein (hsCRP), oral corticosteroid (OCS) dose equivalents normalised to 890 
prednisolone, not applicable (NA).   891 
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number  n=38 n=57 - 
Age (years) 14.2 (11.5-16.2) 13.5 (10.6-15.6) 0.370 
Sex (% female) 39 42 0.798 
FEV1(%) 90 (82-100) 82 (70-94) 0.009 
Asthma control test 23 (22-24) 18 (15-19) <0.0001 
Methacholine (DRS) 3 (0.4-30) 18 (2-61) 0.006 
Atopic (%) 84 83 0.910 
Respiratory allergy (%) 76 77 0.870 
Food allergy (%) 53 37 0.140 
Exacerbations (previous 12 months) 
medians (IQR) 
0 (0-1) 5 (3-10) <0.0001 
ICS (μg budesonide equivalents) 320 (190-400) 800 (800-800) <0.0001 
Anti-leukotriene users (montelukast, n) 0 46 - 
Serum total IgE (IU/mL) 290 (81-765) 283 (118-853) 0.609 
FENO (ppb) 17 (10-26) 22 (10-40) 0.166 
Blood eosinophils (counts/µL) 200 (100-325) 300 (200-585) 0.008 
Serum periostin (ng/mL) 90 (76-119) 84 (56-106) 0.190 
EDN (ng/mmol creatinine)  116 (73-145) 114 (88-173) 0.357 
CysLTs (ng/mmol creatinine)  100 (77-133) 112 (81-162) 0.188 
PGD2-metabolites (ng/mmol creatinine) 65 (44-82) 67 (49-93) 0.359 
All values givens as median (interquartile range, IQR).  Group comparisons were performed by Mann-Whitney U-test or Chisq for categorical variables. 893 
Atopic: sensitized to at least one food or respiratory allergen.  Respiratory allergy: sensitized (>0.35 kuA/L) to one or more of the following allergen sources; 894 
cat, dog, horse, timothy, birch, mugwort, Dermatophagoides pteronyssinus (d.pter), Cladisporium.  Food allergy: sensitized (>0.35 kuA/L) to one or more of 895 
the following allergen sources; milk, egg, wheat, peanut, soya, cod. Methacholine slope of dose-response (DRS), eosinophil derived neuro toxin (EDN), forced 896 
expiratory volume in 1 s pre-bronchodilator (FEV1%), fractional exhaled nitric oxide (FENO), inhaled corticosteroids (ICS).  Concentrations of CysLTs and 897 
PGD2-metabolites were measured by EIA. 898 
  899 
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Table 3. Median (IQR) urinary eicosanoid metabolite concentrations (ng/mmol creatinine) in healthy participants and asthmatics sorted in order of 900 














Smokers and ex-smokers 



















tetranorPGEM (male) 1510 (989-2588)  925 (677-1576) <0.001  1196 (835-1922) 0.043  1665 (1084-2303) 0.025 
tetranorPGEM (female) 701 (482-1152)  656 (433-899) 0.498  698 (533-1166) 0.230  1021 (582-1489) 0.013 
8,12-iso-iPF2α-VI 392 (293-508)  384 (281-506) 0.570  387 (265-549) 0.669  367 (273-508) 0.484 
tetranorPGDM 188 (139-250)  204 (138-285) 0.486  268 (190-368) <0.001  297 (204-410) 0.083 
2,3-dinor-8-iso-PGF2α 171 (124-239)  163 (113-221) 0.390   191 (135-291) 0.009  208 (150-314) 0.153 
PGF2α 97 (75-142)  105 (79-142) 0.460  116 (86-158) 0.039  117 (86-153) 0.647 
2,3-dinor-11β-PGF2α 46 (31-62)  47 (31-68) 0.833  58 (39-80) 0.001  62 (46-83) 0.077 
2,3-dinor-TXB2 42 (30-61)  42 (27-60) 0.908  45 (30-67) 0.567  58 (36-83) 0.006 
8-iso-PGF2α 23 (18-29)  24 (18-33) 0.897  27 (20-39) 0.014  30 (25-43) <0.001 
PGE2 10.0 (5.8-20.0)  10.0 (6.0-15.0) 0.205  15.0 (8.3-23.0) <0.001  14.0 (8.9-24.0) 0.779 
11-dehydro-TXB2 6.8 (3.4-11.0)  6.8 (4.6-9.3) 0.741  8.3 (4.8-13.0) 0.020  9.1 (6.4-14.0) 0.092 
LTE4 3.1 (1.9-4.9)  4.5 (3.1-7-0) <0.001  6.3 (3.9-11.0) <0.001  7.3 (4.3-12.0) 0.304 




Table 4. Evaluation of the effect of oral corticosteroids on urinary eicosanoid metabolite concentrations in subjects with severe asthma. Statistical 904 
comparison was performed using two different criteria: a) subject stratification by reported use of OCS (yes vs. no), b) subject stratification by 905 
criterion (a) plus positive detection of prednisolone† in urine (yes/yes vs. no/no).  906 
Pathway and metabolite  
a) OCS usage according to medical history  b) combined criteria; OCS (yes or no) AND 
detection of urinary prednisolone or its 
metabolites (yes or no) 
 no (n=198) yes (n=168) p-value  no/no (n=167) yes/yes (n=90) p-value 
PGD2        
tetranorPGDM 283 (195-387) 268 (203-368) 0.927  285 (195-386) 272 (216-399) 0.528 
2,3-dinor-11β-PGF2α 60.8 (39.3-78.4) 56.5 (39.5-80.4) 0.778  60.5 (42.8-78.5) 56.6 (37.3-80.9) 0.641 
PGE2         
tetranorPGEM (male) ‡ 1177 (809-2068) 1291 (901-1952) 0.878  1416 (912-2113) 1355 (900-1970) 0.813 
tetranorPGEM (female) ‡ 778 (552-1230) 761 (499-1343) 0.761  790 (555-1246) 743 (501-1313) 0.689 
PGE2 13.3 (7.8-24.8) 15.8 (9.2-23.9) 0.343  14.2 (8.9-25.5) 15.0 (8.3-24.1) 0.654 
PGF2α        
PGF2α 116 (80-155) 118 (88-164) 0.250  116 (82-156) 114 (83-168) 0.771 
TXA2         
11-dehydro-TXB2 8.9 (4.9-13.2) 8.3 (4.7-12.4) 0.557  8.5 (4.9-12.5) 8.7 (5.5-12.6) 0.723 
2,3-dinor-TXB2 50.0 (33.6-76.3) 44.7 (30.5-61.0) 0.017  51.8 (34.0-77.1) 45.1 (30.5-58.1) 0.044 
Isoprostanes        
8-iso-PGF2α 26.7 (19.5-36.2) 28.9 (21.7-40.8) 0.063  26.8 (20.0-37.0) 28.8 (21.5-39.0) 0.349 
2,3-dinor-8-iso-PGF2α 202 (136-295) 183 (134-290) 0.314  204 (137-295) 170 (121-271) 0.058 
8,12-iso-iPF2α-VI 407 (282-550) 350 (248-498) 0.038  419 (295-550) 335 (244-517) 0.036 
Cysteinyl-leukotrienes        
LTE4 6.9 (4.1-10.2) 6.3 (3.9-12.2) 0.719  6.7 (4.3-9.9) 6.5 (4.1-12.4) 0.572 
Values are presented as concentration median (interquartile range, IQR) expressed in ng/mmol creatinine. In (a) subjects reporting daily to weekly OCS are 907 
classified ‘yes’, while subjects reporting never or previous OCS use are classified ‘no’. oral corticosteroids (OCS). Data are presented as median (IQR). Mann-908 
Whitney U-test, nonparametric. †Positive detection was defined by the presence of prednisolone or prednisone, methylprednisolone, 16α-OH-prednisolone, 909 
20β-dihydroprednisolone, or desacetyl deflazacort in urine.  ‡For tetranorPGEM, the number of male subjects in (a) 73=no and 69=yes, female subjects 125=no 910 
and 99=yes. In (b) male subjects in no/no=64 and yes/yes=41, female subjects no/no=103 and yes/yes=49.  911 
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Table 5.  Clinical and biochemical characteristics of 302 adult severe asthma subjects at 912 
baseline and the 12-18 months longitudinal visit in the U-BIOPRED study. 913 
 
Baseline Longitudinal p-value 
Sex (% female) 60% 60% - 
FEV1 (%) 65 (19-82) 64 (16-82) 0.100 
FENO (ppb) 26 (15-46) 23 (15-41) 0.251 
Blood eosinophils (counts/µL) 200 (100-400) 200 (100-400) 0.592 
Sputum eosinophils (%) 2.8 (0.4-13) 2.0 (0.4-11) 0.442 
Serum IL-13(pg/mL) 0.58 (0.30-1.14) 0.65 (0.32-1.23) 0.576 
Serum periostin (ng/mL) 49 (40-60) 51 (42-63) 0.196 
ACQ-5 2.2 (1.4 -3.0) 2.0 (1.0-3.2) 0.449 
AQLQ 4.5 (3.5-5.5) 4.4 (3.5-5.4) 0.515 
†OCS detected (% yes) 28 32 0.368 
Urine prednisolone (ng/mL) 1391 (498-2842) 1250 (664-2724) 0.931 
Urine LTE4 (ng/mmol creatinine) 6.4 (3.9-11.3) 6.2 (3.6-10.4) 0.211 
Urine tetranorPGDM (ng/mmol creatinine) 279 (198-382) 261 (174-384) 0.131 
All values givens as median (interquartile range, IQR). Group comparisons were performed by Mann-914 
Whitney U test. Asthma control questionnaire mean of 1-5 (ACQ-5), asthma quality of life 915 
questionnaire total mean (AQLQ), forced expiratory volume in 1 s pre-bronchodilator (FEV1%), 916 
fractional exhaled nitric oxide (FENO), oral corticosteroids (OCS). †Positive detection was defined by 917 
the presence of prednisolone or prednisone, methylprednisolone, 16α-OH-prednisolone, 20β-918 
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